Learning Objectives
Upon completion of this activity, participants should be able to:
Review data on the safety and efficacy of the investigational protease inhibitors (PIs) tipranavir and TMC114 in highly-PI-experienced patients.
Discuss advances in the development of new reverse transcriptase inhibitors, including NRTIs, NNRTIs, and novel reverse transcriptase inhibitors.
Discuss recent findings on the following novel classes of antiretrovirals: CCR5 inhibitors, integrase inhibitors, and maturation inhibitors.
Earn CME credit by reading the expert analysis and commentary on Antiretroviral Agents. Topics covered include:
-
Novel Reverse Transcriptase Inhibitors
-
Advances in Nonnucleoside Reverse Transcriptase Inhibitors
-
Further Analysis of Tipranavir/Ritonavir in Highly PI-Experienced Patients
-
Use of TMC114/Ritonavir in Highly PI-Experienced Patients
-
Other Investigational Protease Inhibitors
-
Advances in the Development of CCR5 Inhibitors
-
Integrase Inhibitors, Maturation Inhibitors, and Gene Therapy